Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2025 09:10 ET | Source: AlphaMeld Corporation

AlphaMeld Corporation and VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance to Transform Metabolic and Liver Disease Therapeutics

AlphaMeld and VedTechBio form AI-driven alliance to advance first-in-class therapies for obesity, liver, and metabolic diseases with global reach.
January 28, 2025 10:00 ET | Source: AlphaMeld Corporation

AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform

GUILFORD, Conn., Jan. 28, 2025 (GLOBE NEWSWIRE) -- AlphaMeld Corporation, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to...
January 13, 2025 10:00 ET | Source: InveniAI LLC

InveniAI Announces Launch of AlphaMeld Corporation and Major Milestone Updates to Reflect Cutting-Edge Innovation in AI-Driven Drug Discovery

GUILFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize...
February 19, 2024 02:00 ET | Source: InveniAI LLC

InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery

Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...
April 04, 2023 08:43 ET | Source: InveniAI LLC

InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development

Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...
May 31, 2022 08:15 ET | Source: InveniAI LLC

InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration

GUILFORD, Conn. and TOKYO, May 31, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug and target discovery...
February 24, 2022 12:39 ET | Source: InveniAI LLC

InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools

GUILFORD, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development,...
December 16, 2021 08:10 ET | Source: InveniAI LLC

InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas

Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...
July 20, 2021 08:10 ET | Source: InveniAI LLC

InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates

- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...
July 06, 2021 08:10 ET | Source: InveniAI LLC

Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration

Collaboration to create transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early...